2981 T3D2939 Naratriptan Naratriptan is only found in individuals that have used or taken this drug. It is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist.Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism. 121679-13-8 4440 C17H25N3O2S 335.166750 White powder. 246°C (HCl salt) 35 mg/mL Well absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours. The rate of absorption is slower during a migraine attack. Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism. Primarily hepatic. <i>In vitro,</i> naratriptan is metabolized by a wide range of cytochrome P450 isoenzymes into a number of inactive metabolites. Half Life: 5-8 hours No indication of carcinogenicity to humans (not listed by IARC). For the acute treatment of migraine attacks with or without aura in adults. Symptoms of overdose include light-headedness, loss of coordination, tension in the neck, and tiredness. There is no specific antidote to naratriptan. Standard supportive treatment should be applied as required. If the patient presents with chest pain or other symptoms consistent with angina pectoris, ECG monitoring should be performed for evidence of ischemia. (L1712) 2009-07-21T20:28:01Z 2014-12-24T20:25:53Z Naratriptan C07792 7478 Naratriptan DB00952 true CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1 C17H25N3O2S InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3 InChIKey=AMKVXSZCKVJAGH-UHFFFAOYSA-N 335.464 335.166747749 Exogenous Solid 1.6 HMDB15087 CHEMBL1278 4287 <p>Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan, Sandip Vasant Chikhalikar, Maruti Ghagare, &#8220;Process for the synthesis of naratriptan.&#8221; U.S. Patent US20120220778, issued August 30, 2012.</p>